Side effects and adverse reactions of neratinib/neratinib (He Li'an)

Neratinib/Neratinib (Neratinib) is an irreversible HER2 and EGFR receptor tyrosine kinase inhibitor, mainly used for extended adjuvant treatment of HER2-positive breast cancer and advanced or metastatic breast cancer. It inhibits the proliferation and survival of tumor cells by blocking the HER2 signaling pathway. However, while inhibiting tumor cells, it may also affect normal tissues, causing certain side effects and adverse reactions. In clinical practice, the most common adverse reaction is diarrhea, especially in the early stages of treatment. The occurrence of diarrhea is closely related to the interference of drugs on intestinal epithelial cells and EGFR signaling, and can be controlled through dietary adjustments, fluid rehydration, and the use of antidiarrheal drugs under the guidance of a doctor.

In addition, patients may experience gastrointestinal discomfort such as nausea, vomiting, loss of appetite, abdominal pain, etc. These reactions usually gradually subside within a few weeks of taking the medication. Some patients may experience fatigue, hand-foot syndrome or rashes, or even mouth ulcers and mild liver function abnormalities. Therefore, during neratinib treatment, regular monitoring of liver function, blood routine and electrolyte indicators is crucial. A small number of patients may have cardiovascular risks, such asQT interval prolongation, especially those with pre-existing heart disease. ECG evaluation should be performed before taking the drug and regular follow-up should be performed.

Generally speaking, most of the adverse reactions of neratinib are controllable. Through reasonable dose adjustment, adjuvant treatment and regular follow-up, treatment safety can be ensured to the greatest extent. Patients should maintain good living habits while taking the medicine, such as regular work and rest, reasonable diet and adequate water intake, and contact the doctor in time when obvious discomfort occurs to avoid worsening of the condition or affecting the efficacy of the medicine.

Reference materials:https://en.wikipedia.org/wiki/Neratinib